Syracuse, NY, October 31, 2016 – NCODA (National Community Oncology Dispensing Association, Inc.) would like to highlight a major victory in the treatment landscape for oncology patients. On Thursday, October 27, CVS Health announced it had reversed its decision to limit Medicare Part D access away from oncology practices with in office dispensing as of January 1, 2017. “Limiting the options of Medicare Part D patients would have been a major blow to the continuity of quality care which in-office dispensing offers to patients”, said Jim Schwartz, President of NCODA.
In a message from CVS Health “Oncologists who dispense medications will remain in our Medicare Part D networks pending future dialogue with CMS.” This decision is attribute to feedback from oncologists, pharmacists, patients, media and continued communication with CMS.
“NCODA has been right in the middle of this issue, continuing to partner across the patient care continuum to offer the best of care for our oncology patients”, said Michael Reff, Executive Director of NCODA.
NCODA is founded on the vision to deliver positive outcomes through collaboration with all stakeholders involved in the care of oncology patients. NCODA maintains its position that the best site for treatment of cancer patients is with their local oncology team and to create an environment that results in positive change for the cancer patient in the community setting.
NCODA is a grassroots, not-for-profit organization, founded to strengthen community oncology practices with dispensing services. NCODA is addressing the growing need for dispensing cancer clinics to improve operations at the pharmacy level in order to deliver quality and sustainable value to all stakeholders involved in the care of cancer patients’ receiving oral therapy. NCODA brings value to patients and practices through adoption of quality standards, sharing of best practices and improving financial viability.
P.O. Box 308
East Syracuse, NY 13057